Circio Holding ASA: Registration of share capital increase following rights issue and private placement
Idag, 12:19
Oslo, 12 February 2026: Reference is made to the stock exchange announcement published by Circio Holding ASA (the “Company”) on 30 January 2026, regarding the final results of the rights issue raising gross proceeds of NOK 50 million (the “Rights Issue”) and the private placement, raising gross proceeds of approximately NOK 15 million (the “Private Placement”).
The share capital increase related to the Rights Issue and the Private Placement, including the 2,662,000 shares issued as commission to the pre-subscribers in the Rights Issue, as resolved by the extraordinary general meeting held on 12 January 2026, have been registered with the Norwegian Register of Business Enterprises today, 12 February 2026.
The Company’s new share capital is NOK 126,784,012.20 divided into 211,306,687 shares, each with a nominal value of NOK 0.60. The shares are expected to be issued and delivered tomorrow, on 13 February 2026.
The share capital increase related to the directed issue of NOK 3.6 million, as announced on 6 February, will be registered with the Norwegian Register of Business Enterprises as soon as practically possible.
It is to be noted that the final number of shares issued in the Private Placement was adjusted following a final counting, compared to what was announced in the stock exchange announcement published on 30 January 2026. The share capital increase from the Private Placement is NOK 9,011,367.00 through the issuance of 15,018,945 new shares, not 14,992,792 new shares as initially announced.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com
About Circio
Buildingcircular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.
Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 40-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.
In parallel, Circio is continuing to develop its legacy immuno-oncology program, TG01, through cost-efficient external academic and industry collaborations. TG01 targets RAS-mutated cancers and is being tested in two clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine adjuvanted by STIMULON QS-21 licensed from Agenus Inc.
Ämnen i artikeln
Circio Holding ASA: Registration of share capital increase following rights issue and private placement
Idag, 12:19
Oslo, 12 February 2026: Reference is made to the stock exchange announcement published by Circio Holding ASA (the “Company”) on 30 January 2026, regarding the final results of the rights issue raising gross proceeds of NOK 50 million (the “Rights Issue”) and the private placement, raising gross proceeds of approximately NOK 15 million (the “Private Placement”).
The share capital increase related to the Rights Issue and the Private Placement, including the 2,662,000 shares issued as commission to the pre-subscribers in the Rights Issue, as resolved by the extraordinary general meeting held on 12 January 2026, have been registered with the Norwegian Register of Business Enterprises today, 12 February 2026.
The Company’s new share capital is NOK 126,784,012.20 divided into 211,306,687 shares, each with a nominal value of NOK 0.60. The shares are expected to be issued and delivered tomorrow, on 13 February 2026.
The share capital increase related to the directed issue of NOK 3.6 million, as announced on 6 February, will be registered with the Norwegian Register of Business Enterprises as soon as practically possible.
It is to be noted that the final number of shares issued in the Private Placement was adjusted following a final counting, compared to what was announced in the stock exchange announcement published on 30 January 2026. The share capital increase from the Private Placement is NOK 9,011,367.00 through the issuance of 15,018,945 new shares, not 14,992,792 new shares as initially announced.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com
About Circio
Buildingcircular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.
Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 40-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.
In parallel, Circio is continuing to develop its legacy immuno-oncology program, TG01, through cost-efficient external academic and industry collaborations. TG01 targets RAS-mutated cancers and is being tested in two clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine adjuvanted by STIMULON QS-21 licensed from Agenus Inc.
Ämnen i artikeln
Lock-up
Analyser
Mest läst
Lock-up
Analyser
Marknadsöversikt
1 DAG %
Senast
1 mån
